Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cefotaxime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Treatment of lower respiratory tract infections,Urinary tract infections,Septicemia,Intra-abdominal infections,Gynecologic infections,Skin and skin structure infections,Bone and joint infections,Central nervous system infections (e.g., meningitis),Surgical prophylaxis,Off-label: Lyme disease, typhoid fever
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
1-2 g IV every 8 hours; maximum 12 g/day. For severe infections, 2 g every 8 hours.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Terminal elimination half-life ~0.8-1.4 hours in adults with normal renal function. Prolonged to 4-8 hours in severe renal impairment (Cr Cl <20 m L/min).
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Partially metabolized in the liver to desacetylcefotaxime (active metabolite), primarily excreted unchanged via kidneys.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Renal: ~80-90% unchanged via glomerular filtration and tubular secretion. Biliary: <5%. Fecal: minimal.
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
~35%, primarily to albumin.
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
0.25-0.5 L/kg in adults; higher in neonates (0.5-0.7 L/kg). Reflects distribution into extracellular fluid.
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
IM: ~100%.
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
Cr Cl 50-80 m L/min: 1-2 g every 8-12 hours; Cr Cl 20-49 m L/min: 1-2 g every 12-24 hours; Cr Cl 5-19 m L/min: 1-2 g every 24 hours; Cr Cl <5 m L/min: 1-2 g every 48 hours. Hemodialysis: 1-2 g after each dialysis session.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
No adjustment required for Child-Pugh A. Child-Pugh B/C: No specific guidelines; monitor for adverse effects.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Neonates 0-7 days: 50 mg/kg IV every 12 hours; Neonates 8-28 days: 50 mg/kg IV every 8 hours; Infants/children 1 month-12 years: 50 mg/kg IV every 8 hours (max 2 g/dose); Children >12 years: same as adult.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
No specific dose adjustment based on age alone; adjust dose based on renal function as per renal adjustment guidelines.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
No FDA black box warning.
None.
Hypersensitivity reactions including anaphylaxis, Clostridioides difficile-associated diarrhea, seizures (especially in renal impairment), superinfection, prolonged use may lead to bacterial resistance, caution in patients with history of gastrointestinal disease (colitis), and renal impairment requires dose adjustment.
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hypersensitivity to cefotaxime or any cephalosporin, history of severe immediate hypersensitivity reaction to penicillins or other beta-lactams.
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
Avoid alcohol and alcohol-containing foods or medications (e.g., mouthwash, cough syrups) during treatment and for 72 hours after stopping due to risk of disulfiram-like reaction. No other food interactions known.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
Cefotaxime is classified as FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects. There are no adequate and well-controlled studies in pregnant women. Risks to the fetus are considered low; however, cefotaxime should be used during pregnancy only if clearly needed.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Cefotaxime is excreted into human breast milk in low concentrations. The M/P ratio has not been established. It is generally considered compatible with breastfeeding due to low oral bioavailability in infants. Caution is advised with monitoring for potential effects on infant gastrointestinal flora.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
Pregnancy-induced physiological changes (increased plasma volume, enhanced renal clearance) may necessitate higher doses of cefotaxime to achieve therapeutic concentrations. Dose adjustments should be based on clinical response and therapeutic drug monitoring if available. Standard dosing regimens are typically effective, but consider upward adjustment in severe infections.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
Claforan (cefotaxime) is a third-generation cephalosporin with broad-spectrum gram-negative coverage, including many Enterobacteriaceae. In sodium chloride 0.9% (NS), it is stable for 24 hours at room temperature. Administer over 30 minutes for intermittent infusion. Note: Cross-allergenicity with penicillins occurs in ~10% of patients; use caution. Monitor renal function in elderly and high-dose therapy. For surgical prophylaxis, give within 60 minutes before incision. May cause a disulfiram-like reaction with alcohol due to the NMTT side chain. Adjust dose in severe renal impairment (Cr Cl <20 m L/min: decrease dose or extend interval).
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
Do not drink alcohol or take any products containing alcohol while on this medication and for 72 hours after stopping; doing so may cause severe nausea, vomiting, flushing, and headache.,Complete the full course of antibiotics as prescribed, even if you feel better.,Report any signs of allergic reaction such as rash, itching, swelling, or difficulty breathing immediately.,Notify your doctor if you experience severe diarrhea, especially watery or bloody stools, which may indicate C. difficile infection.,This medication is given intravenously; do not mix with other medications unless instructed by your healthcare provider.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Cefotaxime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 1-2 g IV every 8 hours; maximum 12 g/day. For severe infections, 2 g every 8 hours.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Cefotaxime is classified as FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects. There are no adequate and well-controlled studies in pregnant women.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.